The TME was evaluated to determine key aspects of pIL-12 GET and combination treatment related to therapeutic outcomes, particularly the abundance of infiltrating T cells in tumor tissue (Figure 2C) and levels of IFN-γ and IL-12 within the TME. The gene discussed is IFNG; the disease is neoplasm.